CN101687874B - 吡咯并三嗪激酶抑制剂 - Google Patents

吡咯并三嗪激酶抑制剂 Download PDF

Info

Publication number
CN101687874B
CN101687874B CN2008800205589A CN200880020558A CN101687874B CN 101687874 B CN101687874 B CN 101687874B CN 2008800205589 A CN2008800205589 A CN 2008800205589A CN 200880020558 A CN200880020558 A CN 200880020558A CN 101687874 B CN101687874 B CN 101687874B
Authority
CN
China
Prior art keywords
substituted
group
alkyl
heteroaryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800205589A
Other languages
English (en)
Chinese (zh)
Other versions
CN101687874A (zh
Inventor
安东尼·J·桑波格纳罗
马克·D·威特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101687874A publication Critical patent/CN101687874A/zh
Application granted granted Critical
Publication of CN101687874B publication Critical patent/CN101687874B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800205589A 2007-04-18 2008-04-17 吡咯并三嗪激酶抑制剂 Expired - Fee Related CN101687874B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91244607P 2007-04-18 2007-04-18
US60/912,446 2007-04-18
PCT/US2008/060551 WO2008131050A1 (en) 2007-04-18 2008-04-17 Pyrrolotriazine kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101687874A CN101687874A (zh) 2010-03-31
CN101687874B true CN101687874B (zh) 2013-01-30

Family

ID=39544952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800205589A Expired - Fee Related CN101687874B (zh) 2007-04-18 2008-04-17 吡咯并三嗪激酶抑制剂

Country Status (5)

Country Link
US (1) US8198438B2 (https=)
EP (1) EP2134716A1 (https=)
JP (1) JP5319659B2 (https=)
CN (1) CN101687874B (https=)
WO (1) WO2008131050A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982033B2 (en) 2006-11-03 2011-07-19 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8268998B2 (en) 2006-11-03 2012-09-18 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
JP2011513419A (ja) 2008-03-06 2011-04-28 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
US20110269740A1 (en) * 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
US8445676B2 (en) * 2008-10-08 2013-05-21 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
CN102918045A (zh) 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
CN104271580B (zh) * 2012-05-04 2017-02-22 默克专利股份公司 吡咯并三嗪酮衍生物
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
EP2970294B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN108341819B (zh) * 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026297T2 (de) 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
BRPI0407282A (pt) * 2003-02-05 2006-01-31 Bristol Myers Squibb Co Processo para preparação de inibidores de pirrolotriazina cinase
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
WO2006035061A1 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
HRP20140688T1 (hr) * 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
WO2008131050A1 (en) 2008-10-30
JP2010524957A (ja) 2010-07-22
US20100113454A1 (en) 2010-05-06
CN101687874A (zh) 2010-03-31
JP5319659B2 (ja) 2013-10-16
EP2134716A1 (en) 2009-12-23
US8198438B2 (en) 2012-06-12

Similar Documents

Publication Publication Date Title
CN101687874B (zh) 吡咯并三嗪激酶抑制剂
JP5282091B2 (ja) トリアジンキナーゼ阻害剤
EP2049542B1 (en) Pyrrolotriazine kinase inhibitors
CN101600714B (zh) 吡咯并吡啶激酶抑制剂
CN101511835B (zh) 吡咯并三嗪激酶抑制剂
EP2344504B1 (en) Pyrrolotriazine kinase inhibitors
CN101535312B (zh) 吡咯并三嗪激酶抑制剂
US20080045496A1 (en) Pyrrolotriazine kinase inhibitors
CN102596954A (zh) Jak2抑制剂及其用于治疗骨髓增生性疾病及癌症的用途
US8212031B2 (en) Pyrrolotriazine kinase inhibitors
CN101679406A (zh) 用作激酶抑制剂的噻唑基化合物
JP5286281B2 (ja) アミノピラゾールキナーゼ阻害剤
US20110245252A1 (en) Pyrrolotriazine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130130

Termination date: 20150417

EXPY Termination of patent right or utility model